BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The European School of Multimodality Imaging & Therapy (ESMIT) - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://esmit.eanm.org
X-WR-CALDESC:Events for The European School of Multimodality Imaging & Therapy (ESMIT)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Vienna
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20280326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20281029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250301T080000
DTEND;TZID=Europe/Vienna:20270330T170000
DTSTAMP:20260421T212204
CREATED:20251117T100100Z
LAST-MODIFIED:20251117T102105Z
UID:3297-1740816000-1806426000@esmit.eanm.org
SUMMARY:Fundamentals of Research in Imaging and Theranostics Part 2
DESCRIPTION:UEMS EACCME has granted the accreditation of 4.5 CME credits for this event. \n\n\n\n \n\n\n\n \n\n\n\nThis online course is part of a longer line of research methodology which is aimed at providing interested participants with information about the preclinical development and clinical translation\, as well as the design\, conductance and reporting of clinical research trials\, with a specific emphasis on radiopharmaceuticals for both diagnostic and therapeutic applications. \n\n\n\n \n\n\n\n\n\n\n\n \n\n\n\nSave yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!\n\n\n\n \n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n \n\n\n\nFor phase I/II clinical studies with radiopharmaceuticals to understand:    \n\n\n\n\nThe principles of technical realisation of the study including assessment of safety of investigational medicinal product \n\n\n\nThe statistical considerations\, including the estimation of number of subjects to be enrolled  \n\n\n\nThe regulatory requirements for performing clinical studies with radiopharmaceutical with special focus on diagnostic radiopharmaceuticals and to summarise the particularities of these studies \n\n\n\nThe ethical and medical considerations in common and vulnerable populations \n\n\n\nThe principles of preparing the clinical study protocol  \n\n\n\nThe objectives\, endpoints and outcome measures  \n\n\n\nThe principles of patient selection\, inclusion and non-inclusion criteria \n\n\n\nThe principles of establishment of the standard of truth\, the role of the comparator\, superiority/non-inferiority/equivalence(?) studies) & practical examples\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n \n\n\n\n\nPersonnel involved in designing and/or performing phase I/II clinical research with diagnostic radiopharmaceuticals (e.g. nuclear medicine physicians\, pharmacists\, physicists\, nurses\, technologist\, administrative staff). \n\n\n\nPersonnel involved in assessment of the ethical\, medical and methodologic aspects of phase I/II research protocols with diagnostic radiopharmaceuticals. \n\n\n\nAll professionals interested in phase I/II clinical research with diagnostic radiopharmaceuticals \n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n \n\n\n\n\n\nChiara GranaSpeaker \n\n\n\n\n\nBart de KeizerSpeaker \n\n\n\n\n\nCaroline StokkeSpeaker \n\n\n\n\n\nJean-Noel TalbotSpeaker \n\n\n\n\n\n\n\nLuisa Roldao PereiraSpeaker \n\n\n\n\n\nJohn Andrei IagaruSpeaker \n\n\n\n\n\nSona BalogovaSpeaker
URL:https://esmit.eanm.org/event/fundamentals-of-research-part-2/
CATEGORIES:Online Course,Research Methods,Self-paced Online Course,Theranostics
ORGANIZER;CN="ESMIT":MAILTO:esmit@eanm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250404T133000
DTEND;TZID=Europe/Vienna:20250404T143000
DTSTAMP:20260421T212204
CREATED:20241017T080415Z
LAST-MODIFIED:20250326T095143Z
UID:1928-1743773400-1743777000@esmit.eanm.org
SUMMARY:Radioiodine-Refractory Thyroid Cancer - Is it Time to Change the Definition in the Light of Novel Redifferentiation Therapies?
DESCRIPTION:This webinar explores the perspectives on radiorefractory thyroid cancer through two presentations. In the first talk the speaker challenges current diagnostic frameworks and proposes a new vision that better reflects the evolving understanding of refractory thyroid cancer. The second presentation offers a comprehensive review of emerging approaches to restore iodine avidity in radiorefractory thyroid cancer\, highlighting recent clinical trials\, molecular targeting techniques\, and potential promising combination therapies. \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nTo evaluate the current definition of radiorefractory thyroid cancer and identify its limitations in clinical practice\n\n\n\nTo learn new insights for radiorefractory thyroid cancer definition and their potential impact on treatment decisions\n\n\n\nTo learn current evidence-based redifferentiation strategies for restoring iodine avidity in radiorefractory thyroid cancer\n\n\n\nTo improve knowledge of redifferentiation mechanisms to develop personalized treatment plans for patients with radiorefractory thyroid cancer\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nNuclear Medicine physicians\, Endocrinologist\, Oncologist \n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n \n\n\n\n\n\nPetra PetranovicSpeaker \n\n\n\n\n\nMichael KreisslSpeaker \n\n\n\n\n\nLuca GiovanellaModerator \n\n\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/radioiodine-refractory-thyroid-cancer-is-it-time-to-change-the-definition-in-the-light-of-novel-redifferentiation-therapies/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250410T090000
DTEND;TZID=Europe/Vienna:20250411T160000
DTSTAMP:20260421T212204
CREATED:20241017T083229Z
LAST-MODIFIED:20250318T094444Z
UID:1955-1744275600-1744387200@esmit.eanm.org
SUMMARY:Treatment of Metastatic Bone Pain Using Bone-Seeking Agents
DESCRIPTION:Internal radiotherapy with bone-seeking agents is effective in delivering high doses of radiation to widespread metastatic bone lesions and may limit the radiation absorbed dose to healthy tissue. Beta emitter have long been preferred agents for bone pain palliation. The approval of 223Ra and data showing a prolonged survival with alpha emitter are favored in bone pain palliation. Unfortunately\, we do not have good data on the survival after treatment with beta emitters. In the face-to-face course we will discuss the pathophysiology of bone pain to understand the principle of therapeutic effect of bone seeking agents. Dosimetry is essential to increase the dose to the tumor by limiting of severe side effects. All the focus is on the alpha emitters only\, based on the poor data about survival data for the beta emitters. The future of therapy in Nuclear Medicine is the combination with other agents to improve the therapeutic effect\, e.g. chemotherapy\, immunotherapy or anti-androgen therapy. \n\n\n\n\n\n\n\nRegister nowClick on the button to sign up for the course. Register now\n\n\n\n\n\n\n\n\nLearning Objectives\n\n\n\n\nPathophysiology and medical treatment of bone pain\n\n\n\nPro/con alpha/beta emitters\n\n\n\nPerforming of dosimetry\n\n\n\nCombination treatment to improve the therapeutic effect\n\n\n\n\n\n\nTarget Audience\n\n\n\n\nNuclear medicine physician\, junior or senior\, with an interest in treatment\n\n\n\n\n\n\n\n\n\nProgrammeView the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\nKnut LiepeSpeakerFrankfurt (Oder)\, Germany \n\n\n\n\nTatiana LouroSpeakerLisbon\, Portugal \n\n\n\n\n\nGiulia SantoSpeakerCatanzaro\, Italy \n\n\n\n\n\nRegistration Details\n\n\n\nRegistration FeeMode of PaymentCancellation Policy\n\nCourse Fee               € 950.- \n\n\n\nRegistration Fee includes: \n\n\n\n\nElectronic Course Book\, including all Slides\n\n\n\nCoffee & Lunch Breaks\n\n\n\n\nRegistration Fee does NOT include: \n\n\n\n\nTravel to the Venue\n\n\n\nAccommodation\n\n\n\n\n\n\nRegistration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline\, the registration needs to be cancelled. Payment can be settled by Credit Card Cheques will not be accepted \n\n\n\n\n\nCancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course\, we will refund you the fee less a € 100\,- administration charge. After this date\, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels\, airlines or other means of transportation.
URL:https://esmit.eanm.org/event/treatment-of-metastatic-bone-pain-using-bone-seeking-agents/
LOCATION:Future Health Lab\, Alfred-Adler-Straße 1\, Vienna\, 1100\, Austria
CATEGORIES:Onsite Course,Theranostics
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250425T000000
DTEND;TZID=Europe/Vienna:20260425T235959
DTSTAMP:20260421T212204
CREATED:20250225T141140Z
LAST-MODIFIED:20250605T144111Z
UID:2257-1745539200-1777161599@esmit.eanm.org
SUMMARY:Highlights of Focus Meeting 6: Shaping the Future of Breast Cancer Care with Molecular Imaging
DESCRIPTION:Breast cancer remains the most frequently diagnosed cancer and the leading cause of cancer-related death in women worldwide. Despite significant advancements in imaging and treatment\, clinical practice remains heterogeneous across institutions and disciplines. Molecular imaging has a pivotal role in breast cancer care\, from diagnosis to recurrence assessment. To address these discrepancies and define the future direction of imaging in breast cancer\, the European Association of Nuclear Medicine (EANM) devoted its 6th Focus Meeting to this topic\, under the following motto “Shaping the Future of Breast Cancer Care with Molecular Imaging”. \n\n\n\n \n\n\n\nThe aims of this project were: \n\n\n\n\nTo define the role of imaging in breast cancer\, particularly the utility of nuclear medicine techniques in different clinical settings (including initial systemic staging\, assessment of response to therapy\, and detection of recurrence). \n\n\n\nTo reach a multidisciplinary consensus on the current state of the art in nuclear medicine imaging in breast cancer.\n\n\n\nTo generate expert recommendations on how best to guide professionals in their clinical decisions\, beyond the existing guidelines. \n\n\n\nTo identify knowledge gaps and topics with lack of scientific evidence for potential future studies.\n\n\n\n\n \n\n\n\n \n\n\n\nThe recordings in this course are sponsored by Novartis. \n\n\n\n\n\n\n\n\n\nRegister nowEnrol in the online course now for free! Register now\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\n\nIsabel T. RubioSpeaker \n\n\n\n\n\nFrederique Penault LlorcaSpeaker \n\n\n\n\n\nThiemo van NijnattenSpeaker \n\n\n\n\n\nElizabeth DibbleSpeaker \n\n\n\n\n\nTessa BuckleSpeaker \n\n\n\n\n\nKatja Pinker DomenigSpeaker \n\n\n\n\n\n\n\n\n\nSofia Carrilho-VazSpeaker \n\n\n\n\n\nMartina Bašić-KoretićSpeaker \n\n\n\n\n\nDavid GroheuxSpeaker \n\n\n\n\n\nGary UlanerSpeaker \n\n\n\n\n\nGeraldine GebhartSpeaker \n\n\n\n\n\nWolfgang WeberSpeaker \n\n\n\n\n\n\n\n\n\nValeria RomeoSpeaker \n\n\n\n\n\nAlessandra GennariSpeaker \n\n\n\n\n\nKarolien GoffinSpeaker \n\n\n\n\n\nNadia HarbeckSpeaker \n\n\n\n\n\nPascal BaltzerSpeaker \n\n\n\n\n\nMichel van KruchtenSpeaker \n\n\n\n\n\n\n\n\n\nGary Cook Speaker \n\n\n\n\n\nPaola Anna ErbaSpeaker \n\n\n\n\n\nJoana M RibeiroSpeaker \n\n\n\n\n\nCarolien SchröderSpeaker \n\n\n\n\n\nRitse MannSpeaker \n\n\n\n\n\nPhilipp BackhausSpeaker \n\n\n\n\n\n\n\n\n\nMalene Gubbe Hildebrand Speaker \n\n\n\n\n\nFatima CardosoSpeaker \n\n\n\n\n\nAntoinette AttardSpeaker \n\n\n\n\n\nFrancesco SchnettiniSpeaker \n\n\n\n\n\nSofia RiveraSpeaker \n\n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/highlights-of-focus-meeting-6-shaping-the-future-of-breast-cancer-care-with-molecular-imaging/
LOCATION:Online
CATEGORIES:Clinical Nuclear Medicine,Self-paced Online Course
ORGANIZER;CN="ESMIT":MAILTO:esmit@eanm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250425T133000
DTEND;TZID=Europe/Vienna:20250425T143000
DTSTAMP:20260421T212204
CREATED:20241017T081307Z
LAST-MODIFIED:20250214T105155Z
UID:1936-1745587800-1745591400@esmit.eanm.org
SUMMARY:Highlights of Focus Meeting 6: Shaping the Future of Breast Cancer Care with Molecular Imaging (pre-recorded)
DESCRIPTION:more information coming soon \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nSpeaker \n\n\n\n\n\nSpeaker \n\n\n\n\n\nSpeaker \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/highlights-of-focus-meeting-6-shaping-the-future-of-breast-cancer-care-with-molecular-imaging-prerecorded/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
END:VCALENDAR